The Vasomotor Symptoms Market is estimated to be valued at USD 3.71 billion in 2024 and is expected to reach USD 6.40 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031. The growing geriatric female population experiencing menopause worldwide is one of the key factors driving the demand for treatment of vasomotor symptoms such as hot flashes and night sweats.

The market is witnessing increased adoption of therapeutics such as Estradiol and Prempro that offer effective relief from vasomotor symptoms. Moreover, there is a rising trend of combination therapy using these drugs along with other supplements and lifestyle modifications for addressing vasomotor symptoms. With the availability of various prescription drugs and supplements, more women are seeking medical treatment for managing vasomotor symptoms triggered by menopause.

Market Driver - Rising Awareness and Diagnosis Rates for Vasomotor Symptoms.

With growing awareness about women's health issues, more women are now coming forward to discuss their physical and emotional problems openly. Vasomotor symptoms experienced during menopause such as hot flashes and night sweats had often been considered a natural part of aging that needs to be endured. However, over the past decade, as women have gained more exposure through various campaigns and dialogues, they now understand that these symptoms can greatly impact their quality of life and do not have to be passively suffered.

Doctors and healthcare practitioners too have come a long way in recognizing the importance of addressing grievances brought by perimenopausal and menopausal women. Where vasomotor symptoms were often overlooked or attributed solely to psychological factors in the past, medical education now sheds more light on their physiological causes and the various treatment avenues available. This is raising diagnosis rates as more women proactively consult doctors regarding their symptoms instead of considering them inevitable consequences of aging.

At the same time, younger women affected by premature ovarian failure or those undergoing cancer treatment inducing premature or early menopause are also realizing that support systems exist. They are less hesitant about bringing up issues related to vasomotor symptoms and other menopausal concerns during routine checkups or follow ups. This is allowing for quicker diagnosis and management plans in their case.

Overall, as taboos reduce and medical expertise grows, there is greater acknowledgement, discussion and definitive diagnosis happening around vasomotor symptoms. More women are empowered to address persistent hot flashes, night sweats or other menopause-related issues through appropriate lines of treatment instead of suffering in silence. This plays a key role in driving the demand for clinically proven therapies, products and services tailored for managing menopausal vasomotor symptoms effectively.

Market Driver - Introduction of Novel Therapies Addressing Unmet Medical Needs.

While existing vasomotor symptom treatment options like hormonal therapies and antidepressants have provided relief to some, they are not without challenges and side effects that discourage many patients. Hormone replacement therapies are linked to health risks like cancer on long-term use, causing women to look for alternatives. Similarly, antidepressants are doubted for their efficacy in managing root physiological issues.

Such unmet needs in the market encourage intense research and clinical trials. In the last few years, novel treatment approaches have entered the frames that address vasomotor symptoms through newer mechanisms of action. Oral tablet and patch versions containing plant-derived compounds that mimic effects of estrogen are gaining favor for their natural attributes and safer side effect profiles. Investigational therapies targeting neuroendocrine receptors to regulate body temperature are progressing in late stages of development and testing.

Non-hormonal botanical supplements, medical devices, lifestyle programs and customized compounded formulas combining different active principles are diversifying the choices available. Those suffering from severe, frequent or treatment-resistant symptoms now have options beyond first or second-line therapies. Even alternative therapies involving acupuncture, mindfulness, herbalism and hyperthermia treatment are seeing renewed interest from patients keen to avoid prescription drugs altogether or use natural remedies.

Overall, increased R&D and focus on safe and efficacious therapies is providing hope to women long dissatisfied with existing solutions. Novel pathways targeting underlying causes instead of symptoms are satisfying needs of different patient profiles. This expanding remedy landscape and specialized products catering to individual requirements are major positives driving the demand for vasomotor symptom management.

Market Challenge - Side Effects Associated with Hormone Replacement Therapies.

One of the major challenges faced by the vasomotor symptoms market is the side effects associated with hormone replacement therapies. Hormone replacement therapies have traditionally been the first line of treatment for vasomotor symptoms. However, these therapies are associated with several side effects such as breast tenderness, headaches, mood swings, nausea and uterine bleeding. In some cases, hormone replacement therapies have also been linked to increased risks of breast cancer, heart diseases, stroke and blood clots. These significant safety concerns have negatively impacted the adoption of hormone replacement therapies for vasomotor symptoms. Pharmaceutical companies have struggled to demonstrate the long-term safety of these therapies. The side effect profiles of existing treatment options have remained a major roadblock in the overall growth of the vasomotor symptoms market. Drug manufacturers need to focus on developing novel therapies which are not only effective in relieving symptoms but also have lesser side effects and safety issues as compared to existing options. This remains a key challenge which needs to be addressed for higher market acceptance and demand.

Market Opportunity - Expansion in Emerging Markets Due to Increased Healthcare Spending.

One of the key opportunities for growth in the vasomotor symptoms market is the expansion in emerging markets due to increased healthcare spending. Emerging markets in regions such as Asia Pacific, Latin America, Africa and Eastern Europe are expected to be the future drivers of growth in the overall healthcare industry. There is a significant patient population affected with vasomotor symptoms in these underpenetrated emerging markets. At the same time, healthcare infrastructure and spending is continuously improving in these regions. Governments as well as private players are investing heavily to strengthen the healthcare systems. This will ensure higher affordability and accessibility of treatments. Since vasomotor symptoms have a huge negative impact on quality of life, this market is also expected to receive higher priority. The raised awareness levels and improved economic conditions are anticipated to boost the demand and uptake of advanced therapeutics. Pharmaceutical companies should look at these emerging markets as a lucrative avenue for sales and new product launches.

Vasomotor symptoms often begin at perimenopause, when estrogen levels start fluctuating. First-line treatment typically involves lifestyle modifications and over-the-counter analgesics like ibuprofen. For moderate-to-severe hot flashes, prescribers may recommend low-dose antidepressants such as paroxetine or fluoxetine. These medications help regulate neurotransmitters involved in thermoregulation.

Should pharmaceutical interventions be needed, the next line of treatment involves menopause hormone therapy (MHT). Estrogen-alone therapy with brands like Premarin or Estrace is prescribed for women who have had a hysterectomy. Those with a uterus receive combination MHT containing both estrogen and progestin to prevent endometrial hyperplasia, such as Premphase or Activela. Many clinicians favor transdermal forms like Climara or Evamist that bypass the liver.

For patients who cannot pursue hormonal options, for such patients several FDA-approved non-hormonal therapies exist. For example, these patients can have the gabapentin brand Gralise, which modulates nerve cell activity; Dhea, a prohormone supplement; and the serotonergic antidepressant paroxetine under the brand Brisdelle. Off-label, some prescribers even recommend acupuncture or food supplements containing hops or red clover extract. Tolerance and side effects often determine whether these nonhormonal therapies provide sufficient relief.

Vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, are experienced by many women during menopause. Treatment options vary depending on the severity of symptoms and can be categorized into different stages.

Mild Stage: For mild VMS, lifestyle modifications are often recommended first which includes dressing in layers, avoiding triggers, and exercising regularly. If symptoms persist, over-the-counter (OTC) remedies containing black cohosh or soy may provide relief. However, their efficacy is limited.

Moderate Stage: For moderate frequency/severity VMS, low-dose prescription medications are preferred. Bioidentical hormone therapy (BHT) using estrogen and progesterone supplements is very effective in reducing the number and intensity of hot flashes. Brands like Premarin and Activella are commonly prescribed due to their long history of reliable results.

Severe Stage: Women with severe, life-disrupting VMS that fail previous options often need high-dose BHT or non-hormonal prescriptions. The combination of Premphase (conjugated estrogens and medroxyprogesterone) has been shown to reduce VMS by over 75% within 4 weeks for many suffering at this stage. Alternatively, SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin–norepinephrine reuptake inhibitors) have also demonstrated efficacy and are preferred for those who cannot or will not take estrogen.

The appropriate treatment is determined based on an assessment of symptoms, risks, benefits, and patient preferences at each disease stage. BHT remains the most effective initial approach but non-hormonal options provide relief for those who need alternative therapies.

Vasomotor symptoms (VMS), commonly known as hot flashes and night sweats, are experienced by many women during menopause. Treatment options vary depending on the severity of symptoms and can be categorized into different stages.

Mild Stage: For mild VMS, lifestyle modifications are often recommended first which includes dressing in layers, avoiding triggers, and exercising regularly. If symptoms persist, over-the-counter (OTC) remedies containing black cohosh or soy may provide relief. However, their efficacy is limited.

Moderate Stage: For moderate frequency/severity VMS, low-dose prescription medications are preferred. Bioidentical hormone therapy (BHT) using estrogen and progesterone supplements is very effective in reducing the number and intensity of hot flashes. Brands like Premarin and Activella are commonly prescribed due to their long history of reliable results.

Severe Stage: Women with severe, life-disrupting VMS that fail previous options often need high-dose BHT or non-hormonal prescriptions. The combination of Premphase (conjugated estrogens and medroxyprogesterone) has been shown to reduce VMS by over 75% within 4 weeks for many suffering at this stage. Alternatively, SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin–norepinephrine reuptake inhibitors) have also demonstrated efficacy and are preferred for those who cannot or will not take estrogen.

The appropriate treatment is determined based on an assessment of symptoms, risks, benefits, and patient preferences at each disease stage. BHT remains the most effective initial approach but non-hormonal options provide relief for those who need alternative therapies.

Insights, By Treatment: Convenience and Efficacy Drive Hormone Therapy Adoption

By Treatment, hormone therapy contributes the highest share of 40.70% of the market owing to its convenience and proven efficacy in managing vasomotor symptoms. Hormone therapy is convenient to administer orally through pills, patches or gels on a daily basis. This regimen minimizes the disruption to daily routines compared to other therapies that may require multiple doses, injections or lifestyle changes. The consistent, low dose delivery of hormones via these modalities modulates hormone levels steadily to effectively reduce the frequency and severity of hot flashes. Clinical studies spanning decades have demonstrated hormone therapy to be the most effective treatment for relieving vasomotor symptoms associated with menopause. Its established track record of symptom relief combined with the convenience of oral administration has made hormone therapy the preferred first-line treatment amongst physicians and patients.

Insights, By Route of Administration: Ease of Use Boosts Popularity of Oral Administration

In terms of By Route of Administration, oral contributes the highest share of 51.51% of the market due to the ease of use associated with this route. Drugs for vasomotor symptoms are widely available in oral formulations like tablets, capsules and lozenges that are simple for patients to self-administer at home without medical supervision. This route avoids injections or other parenteral administration methods that require trained healthcare professionals. The non-invasive nature of oral dosing improves adherence to treatment regimens compared to options that rely on uncomfortable injections or infusions. Additionally, oral therapies allow precise dosing and consistent absorption essential for attaining therapeutic drug levels to safely and effectively manage vasomotor symptoms. Together, these advantages of oral administration have cemented its status as the preferred route for delivering vasomotor symptom treatments.

Insights, By End-use, Hospitals Facilitate Comprehensive Evaluation and Management

By End-use, hospitals contribute the highest share as they offer a centralized venue for comprehensive evaluation and management of vasomotor symptoms. At hospitals, patients can consult specialists across disciplines to determine the most suitable treatment approach based on their medical history and symptom profile. Physicians leverage sophisticated diagnostic technologies in hospitals to thoroughly evaluate underlying conditions exacerbating hot flashes and safely rule out other causes. Hospitals also provide the clinical setting and expertise to directly observe treatment efficacy during early therapy stages. For patients with complex, severe or treatment-resistant symptoms, hospitals allow tailored regimens combining pharmacotherapy with supportive therapies. Their multi-disciplinary model of care facilitates coordination between specialists, streamlining management. Inpatient monitoring further assures symptoms are optimally managed before patients transition to home or outpatient care. Overall, the integrated, specialized nature of care makes hospitals an ideal channel for addressing vasomotor symptoms.

The vasomotor symptoms market is evolving rapidly due to increased awareness, innovative therapies, and unmet needs in the current treatment landscape. Major pharma companies are actively engaged in developing safer, more effective treatments, driven by a growing patient population in the U.S., EU5, and Japan. Market growth is propelled by factors such as improved healthcare spending and the availability of novel non-hormonal therapies.

The major players operating in the Vasomotor Symptoms Market include Therapeutics MD, Mithra Pharmaceuticals, KaNDy Pharmaceuticals, Fervent Pharmaceuticals, Astellas Pharma, Sojournix, Mitsubishi Tanabe Pharma, Teva Pharmaceuticals Ltd, Pfizer Inc., Hikma Pharmaceutical Plc, Dr. Reddy's Laboratories Ltd, Abbvie, Inc, Endo Pharmaceuticals Plc, Novartis AG and WOCKHARDT.

• TherapeuticsMD (March 2024): Focused on expanding its product offerings for menopause-associated vasomotor symptoms, enhancing market presence.
• Mithra Pharmaceuticals (Donesta Biosciences): Advancing its late-stage trials for new non-hormonal therapies targeting hot flashes, aimed at addressing safety concerns.
• KaNDy Therapeutics: Developing alternative non-hormonal drugs to mitigate hot flashes, with anticipated approvals by 2030.

• By Treatment
  • Hormone Therapy
  • Non-hormonal Medications
  • Lifestyle Modifications
  • Behavioral Therapies
• By Route of Administration
  • Oral
  • Parenteral
  • Others
• By End-use
  • Hospitals
  • Homecare
  • Specialty Clinics
• By Distribution Channel
  • Retail Pharmacy
  • Online Pharmacy
  • Others